(KIDS) Orthopediatrics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US68752L1008
Stock:
Total Rating 13
Risk 45
Buy Signal -0.01
| Risk 5d forecast | |
|---|---|
| Volatility | 51.1% |
| Relative Tail Risk | -5.46% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.55 |
| Alpha | -41.80 |
| Character TTM | |
|---|---|
| Beta | 0.666 |
| Beta Downside | 0.785 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.07% |
| CAGR/Max DD | -0.40 |
EPS (Earnings per Share)
Revenue
Description: KIDS Orthopediatrics
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -45.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA 4.54 > 1.0 |
| NWC/Revenue: 93.50% < 20% (prev 112.7%; Δ -19.16% < -1%) |
| CFO/TA -0.04 > 3% & CFO -19.2m > Net Income -45.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.4m) vs 12m ago 1.08% < -2% |
| Gross Margin: 71.73% > 18% (prev 0.74%; Δ 7099 % > 0.5%) |
| Asset Turnover: 46.28% > 50% (prev 38.76%; Δ 7.51% > 0%) |
| Interest Coverage Ratio: -6.30 > 6 (EBITDA TTM -14.4m / Interest Expense TTM 5.38m) |
Altman Z'' -1.35
| A: 0.43 (Total Current Assets 245.9m - Total Current Liabilities 33.2m) / Total Assets 493.5m |
| B: -0.54 (Retained Earnings -265.1m / Total Assets 493.5m) |
| C: -0.07 (EBIT TTM -33.9m / Avg Total Assets 491.4m) |
| D: -1.86 (Book Value of Equity -268.7m / Total Liabilities 144.2m) |
| Altman-Z'' Score: -1.35 = CCC |
Beneish M -2.86
| DSRI: 1.00 (Receivables 51.3m/42.8m, Revenue 227.4m/189.7m) |
| GMI: 1.03 (GM 71.73% / 73.68%) |
| AQI: 1.09 (AQ_t 0.40 / AQ_t-1 0.37) |
| SGI: 1.20 (Revenue 227.4m / 189.7m) |
| TATA: -0.05 (NI -45.6m - CFO -19.2m) / TA 493.5m) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of KIDS shares?
As of February 26, 2026, the stock is trading at USD 16.72 with a total of 142,424 shares traded.
Over the past week, the price has changed by -2.17%, over one month by -5.96%, over three months by -12.41% and over the past year by -27.15%.
Over the past week, the price has changed by -2.17%, over one month by -5.96%, over three months by -12.41% and over the past year by -27.15%.
Is KIDS a buy, sell or hold?
Orthopediatrics has received a consensus analysts rating of 4.29.
Therefore, it is recommended to buy KIDS.
- StrongBuy: 3
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KIDS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24 | 43.5% |
| Analysts Target Price | 24 | 43.5% |
KIDS Fundamental Data Overview February 24, 2026
P/S = 1.8702
P/B = 1.2646
Revenue TTM = 227.4m USD
EBIT TTM = -33.9m USD
EBITDA TTM = -14.4m USD
Long Term Debt = 99.2m USD (from longTermDebt, last quarter)
Short Term Debt = 166.0k USD (from shortTermDebt, last quarter)
Debt = 99.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 82.5m USD (from netDebt column, last quarter)
Enterprise Value = 466.9m USD (425.3m + Debt 99.3m - CCE 57.7m)
Interest Coverage Ratio = -6.30 (Ebit TTM -33.9m / Interest Expense TTM 5.38m)
EV/FCF = -15.86x (Enterprise Value 466.9m / FCF TTM -29.4m)
FCF Yield = -6.30% (FCF TTM -29.4m / Enterprise Value 466.9m)
FCF Margin = -12.94% (FCF TTM -29.4m / Revenue TTM 227.4m)
Net Margin = -20.06% (Net Income TTM -45.6m / Revenue TTM 227.4m)
Gross Margin = 71.73% ((Revenue TTM 227.4m - Cost of Revenue TTM 64.3m) / Revenue TTM)
Gross Margin QoQ = 73.92% (prev 72.07%)
Tobins Q-Ratio = 0.95 (Enterprise Value 466.9m / Total Assets 493.5m)
Interest Expense / Debt = 1.83% (Interest Expense 1.82m / Debt 99.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -26.8m (EBIT -33.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.40 (Total Current Assets 245.9m / Total Current Liabilities 33.2m)
Debt / Equity = 0.28 (Debt 99.3m / totalStockholderEquity, last quarter 349.3m)
Debt / EBITDA = -5.72 (negative EBITDA) (Net Debt 82.5m / EBITDA -14.4m)
Debt / FCF = -2.80 (negative FCF - burning cash) (Net Debt 82.5m / FCF TTM -29.4m)
Total Stockholder Equity = 351.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.28% (Net Income -45.6m / Total Assets 493.5m)
RoE = -12.97% (Net Income TTM -45.6m / Total Stockholder Equity 351.6m)
RoCE = -7.53% (EBIT -33.9m / Capital Employed (Equity 351.6m + L.T.Debt 99.2m))
RoIC = -6.13% (negative operating profit) (NOPAT -26.8m / Invested Capital 437.3m)
WACC = 7.06% (E(425.3m)/V(524.7m) * Re(8.37%) + D(99.3m)/V(524.7m) * Rd(1.83%) * (1-Tc(0.21)))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.43%
[DCF] Fair Price = unknown (Cash Flow -29.4m)
EPS Correlation: -11.14 | EPS CAGR: 0.0% | SUE: 0.09 | # QB: 0
Revenue Correlation: 95.35 | Revenue CAGR: 27.25% | SUE: -0.91 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.40 | Chg7d=-0.017 | Chg30d=-0.017 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.04 | Chg7d=-0.010 | Chg30d=-0.010 | Revisions Net=+0 | Growth EPS=-3.1% | Growth Revenue=+11.6%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
P/B = 1.2646
Revenue TTM = 227.4m USD
EBIT TTM = -33.9m USD
EBITDA TTM = -14.4m USD
Long Term Debt = 99.2m USD (from longTermDebt, last quarter)
Short Term Debt = 166.0k USD (from shortTermDebt, last quarter)
Debt = 99.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 82.5m USD (from netDebt column, last quarter)
Enterprise Value = 466.9m USD (425.3m + Debt 99.3m - CCE 57.7m)
Interest Coverage Ratio = -6.30 (Ebit TTM -33.9m / Interest Expense TTM 5.38m)
EV/FCF = -15.86x (Enterprise Value 466.9m / FCF TTM -29.4m)
FCF Yield = -6.30% (FCF TTM -29.4m / Enterprise Value 466.9m)
FCF Margin = -12.94% (FCF TTM -29.4m / Revenue TTM 227.4m)
Net Margin = -20.06% (Net Income TTM -45.6m / Revenue TTM 227.4m)
Gross Margin = 71.73% ((Revenue TTM 227.4m - Cost of Revenue TTM 64.3m) / Revenue TTM)
Gross Margin QoQ = 73.92% (prev 72.07%)
Tobins Q-Ratio = 0.95 (Enterprise Value 466.9m / Total Assets 493.5m)
Interest Expense / Debt = 1.83% (Interest Expense 1.82m / Debt 99.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -26.8m (EBIT -33.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.40 (Total Current Assets 245.9m / Total Current Liabilities 33.2m)
Debt / Equity = 0.28 (Debt 99.3m / totalStockholderEquity, last quarter 349.3m)
Debt / EBITDA = -5.72 (negative EBITDA) (Net Debt 82.5m / EBITDA -14.4m)
Debt / FCF = -2.80 (negative FCF - burning cash) (Net Debt 82.5m / FCF TTM -29.4m)
Total Stockholder Equity = 351.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.28% (Net Income -45.6m / Total Assets 493.5m)
RoE = -12.97% (Net Income TTM -45.6m / Total Stockholder Equity 351.6m)
RoCE = -7.53% (EBIT -33.9m / Capital Employed (Equity 351.6m + L.T.Debt 99.2m))
RoIC = -6.13% (negative operating profit) (NOPAT -26.8m / Invested Capital 437.3m)
WACC = 7.06% (E(425.3m)/V(524.7m) * Re(8.37%) + D(99.3m)/V(524.7m) * Rd(1.83%) * (1-Tc(0.21)))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.43%
[DCF] Fair Price = unknown (Cash Flow -29.4m)
EPS Correlation: -11.14 | EPS CAGR: 0.0% | SUE: 0.09 | # QB: 0
Revenue Correlation: 95.35 | Revenue CAGR: 27.25% | SUE: -0.91 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.40 | Chg7d=-0.017 | Chg30d=-0.017 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.04 | Chg7d=-0.010 | Chg30d=-0.010 | Revisions Net=+0 | Growth EPS=-3.1% | Growth Revenue=+11.6%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)